Skip Navigation



European Heart Journal Advance Access published online on September 29, 2006
European Heart Journal, doi:10.1093/eurheartj/ehl277
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
27/24/2945    most recent
ehl277v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Link, A.
Right arrow Articles by Nickenig, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Link, A.
Right arrow Articles by Nickenig, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

European Heart Journal © The European Society of Cardiology 2006; all rights reserved
Received May 18, 2006
Revised August 18, 2006
Accepted September 11, 2006

Clinical research

Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome

Andreas Link 1 *, Tarek Ayadhi 1, Michael Böhm 1, and Georg Nickenig 2

1 Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, D-66421Homburg/Saar, Germany
2 Medizinische Klinik und Poliklinik II, Universitätsklinikum Bonn, D-53105 Bonn, Germany

* To whom correspondence should be addressed.
Andreas Link, E-mail: link{at}med-in.uni-saarland.de


  Abstract

Aims HMG-CoA reductase inhibitors (statins) reduce cardiovascular mortality and morbidity in patients with stable coronary artery disease as well as acute coronary syndrome (ACS). It is unclear how rapidly the beneficial effects of statins occur in patients with ACS and whether these drug properties are related to lipid lowering.

Methods and results Patients with troponin-positive ACS (n = 35) were randomized to 20 mg/day rosuvastatin therapy or to placebo treatment. Anti-inflammatory effects of rosuvastatin measured by lymphocyte intracellular cytokine production were taken before initiation of treatment and on days 1, 3, and 42. Compared with placebo, rosuvastatin treatment significantly reduced plasma concentrations of pro-inflammatory cytokines TNF-{alpha} and IFN-{gamma} at 72 h. Rosuvastatin also induced a rapid and significant reduction of TNF-{alpha} and IFN-{gamma} production in stimulated T-lymphocytes at 72 h. When compared with placebo, rosuvastatin inhibited the Th-1-immune response measured at 72 h.

Conclusion Rosuvastatin exerts rapid immunomodulatory effects on the level of T-cell activation in patients with ACS.

Keywords: Acute coronary syndromes; Inflammation; Th-1-immune response; Statins.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
M. Moreno, L. N. Ramalho, P. Sancho-Bru, M. Ruiz-Ortega, F. Ramalho, J. G. Abraldes, J. Colmenero, M. Dominguez, J. Egido, V. Arroyo, et al.
Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver
Am J Physiol Gastrointest Liver Physiol, February 1, 2009; 296(2): G147 - G156.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
O. Adam, H.-R. Neuberger, M. Bohm, and U. Laufs
Prevention of Atrial Fibrillation With 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors
Circulation, September 16, 2008; 118(12): 1285 - 1293.
[Full Text] [PDF]

Home page
 J CARDIOVASC PHARMACOL THERHome page
M. S. Kostapanos, H. J. Milionis, and M. S. Elisaf
An Overview of the Extra-Lipid Effects of Rosuvastatin
Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2008; 13(3): 157 - 174.
[Abstract] [PDF]

Home page
 J Am Coll CardiolHome page
R. P. Giugliano and E. Braunwald
The Year in Non ST-Segment Elevation Acute Coronary Syndrome
J. Am. Coll. Cardiol., October 2, 2007; 50(14): 1386 - 1395.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
K. Shimada, J. K. Park, and H. Daida
T helper 1/T helper 2 balance and HMG-CoA reductase inhibitors in acute coronary syndrome: statins as immunomodulatory agents?
Eur. Heart J., December 2, 2006; 27(24): 2916 - 2918.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.